CHILDHOOD chronic myelogenous leukaemia (CML) is rare. Iversen (1966) found only 7 cases among 516 leukaemic children, and Reisman and Trujillo (1963) found 7 in 160 patients under 10 years of age. The Ph' chromosome is not always found (Reisman and Trujillo, 1963; Hardisty, Speed and Till, 1964; Tijo et al., 1966; and Holton and Johnson, 1968) , and it seems reasonable to suppose that Ph1 negative CML is relatively more common in children than in adults. Here we report a case of childhood CML which, as far as we can ascertain, is the earliest onset of Ph1-positive CML recorded, and which has several unusual features.
L.C. is the first child of young healthy non-consanguinous parents. He was born in May 1974 after an uneventful pregnancy. His mother had no infections during pregnancy and had no drugs other than oral iron. No diagnostic x-rays were administered during the pregnancy and no other potentially carcinogenic hazards are known to have been encountered. At the age of 11 months he developed diarrhoeaand vomiting and on examination at that time was found to be a healthy well-grown child with a mild hydrocephalus (H.C. 52 cm). (Bradley and Metcalf, 1966; Pluznik and Sachs, 1966 (Ragab et al., 1974) are given in the Table. In patient L.C. the concentration of CFUC in the peripheral blood was greatly in excess of normal values when initially assayed. During the course of chemotherapy however, a gradual decline was seen. The initial high CFUC numbers and the subsequent response to chemo- Sarin and Gallo, 1974; . It is absent in peripheral blood lymphocytes of normal people . The presence of the enzyme in the peripheral blood of L.C. was confirmed in a second sample taken on 9 October 1975, when the level was 2-9 u/108 cells.
These values are similar to those reported for thymocytes (Coleman et al., 1974) and ALL cells (Sarin and Gallo, 1974; McCaffrey et al., 1975) . The enzyme was identified by its chromatographic properties which were similar to those reported by other workers (Sarin and Gallo, 1974; and its ability to polymerize deoxyguanosine 5'-triphosphate on an oligo (dpA)1218 initiator, thus distinguishing it from a " similar " enzyme reported to be present in murine myeloma (Penit, Paraf and Chapeville, 1975) . On phosphocellulose chromatography a second, early eluting, peak of terminal transferase activity (representing ca 8% of the total activity was observed. Similar earlyeluting peaks of activity have been observed from both human and murine thymocytes (Kung et al., 1975) and in other terminal transferase-positive leukaemias .
The peripheral blood from an agematched haematologically normal child, along with the blood from the mother were also examined for terminal transferase activity. No activity was detected in either of these samples down to a level of ca 0 05 U/108 cells. Previous reports have shown terminal transferase to be absent from the peripheral blood of normal adults down to a level of 0-002 u/108 cells . Due to the difficulty of obtaining sufficient material from normal infants we cannot exclude the possibility that terminal transferase is present in young children at levels below 0 05 U/108 cells.
If, as is generally believed, terminal transferase is specific for thymic or prethymic cells, its presence in the present case is unexpected. Previous studies of CML have shown that terminal transferase is not present at detectable levels in the chronic phase of the disease but appeared at levels comparable with those found in thymocytes and ALL cells in certain cases of CML (1 in 4) which had undergone blast transformation. The appearance of terminal transferase in such cases may be compatible with, and related to, the observation that for 10-15% of CML patients in blast transformation the resulting leukaemic cells seem to have some " lymphoid " characteristics (Boggs, 1974) . If indeed the enzyme is specific for thymic and pre-thymic cells, as suggested by several authors (Coleman et al., 1974; McCaffrey et al., 1975) , the presence of terminal transferase in some blastic CMLs may represent a true " lymphoblastoid " transformation. In L.C., at the time of examination, however, the peripheral blood and bone marrow showed a predominance of maturing myeloid elements and no evidence for blastic crisis. It seems unlikely that the higher levels of terminal transferase found in the samples were derived from the relatively low numbers of lymphocytes present (see case report) since the enzyme is absent from normal peripheral blood lymphocytes and, if it were derived solely from the lymphocytes in L.C. the levels would have to be at least 10 times those reported for ALL cells. The same argument can be applied to the monocytes. During chemotherapy the relative numbers of granulocyte precursor cells (CFUC) fell appreciably. In contrast there was no change in the level of the terminal transferase, indicating that in this case chemotherapy is not selectively removing the terminal transferase-positive cells from the peripheral blood, and further, that the CFUC, as the lymphocytes and monocytes, were not likely to have been the source of the enzyme. This implies that, in this case, the enzyme originated in the maturing myeloid cells.
Other authors (Trujillo and Ohno, 1963) have argued that a pluripotent " stem " cell is involved in CML, since the Ph' chromosome has been demonstrated in both erythroid and granulocytic cells although it is absent in lymphocytes. The finding that a proportion of cases in blast transformation, and in patient L.C. in the chronic phase, show terminal transferase activity (a lymphoid characteristic?) may indicate a " reversion " of cells to earlier (embryonic) characteristics, a phenomenon not unknown in malignant cells. Alternatively, the enzyme may not be restricted to pre-T cells and thymocytes but may be present in many types of cells (albeit at low levels) and a marked enhancement in the levels of the enzyme occurs in certain disease states.
